PASITHEA THERAPEUTICS CORP. Operating Lease, Expense
PASITHEA THERAPEUTICS CORP. (KTTA) reported Operating Lease, Expense of $156.04 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-03-30
- PASITHEA THERAPEUTICS CORP. operating lease, expense for the quarter ending 2024-12-31 was $16.41K, a 93.17% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. operating lease, expense for the quarter ending 2024-09-30 was $17.53K.
- PASITHEA THERAPEUTICS CORP. operating lease, expense for the quarter ending 2024-06-30 was $79.59K, a 8.97% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. operating lease, expense for the quarter ending 2024-03-31 was $42.52K, a 23.04% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. operating lease, expense for fiscal 2024 was $156.04K, a 35.85% decline from fiscal 2023.
- PASITHEA THERAPEUTICS CORP. operating lease, expense for fiscal 2023 was $243.23K, a 44.08% increase from fiscal 2022.
- PASITHEA THERAPEUTICS CORP. operating lease, expense for fiscal 2022 was $168.81K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $16.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $33.94K derived: sum of 2 quarters · filed 2026-03-30 | $113.53K derived: sum of 3 quarters · filed 2026-03-30 | $156.04K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $17.53K 10-Q · filed 2025-11-13 | $97.12K derived: sum of 2 quarters · filed 2025-11-13 | $139.63K 10-Q · filed 2025-11-13 | $379.98K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $79.59K 10-Q · filed 2025-08-14 | $122.10K 10-Q · filed 2025-08-14 | $362.45K derived: sum of 3 quarters · filed 2025-08-14 | $237.05K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $42.52K 10-Q · filed 2025-05-15 | $282.87K derived: sum of 2 quarters · filed 2025-05-15 | $157.47K derived: sum of 3 quarters · filed 2025-05-15 | $230.50K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $240.35K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $114.95K derived: sum of 2 quarters · filed 2025-03-24 | $187.99K derived: sum of 3 quarters · filed 2025-03-24 | $243.23K 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$125.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$52.36K derived: sum of 2 quarters · filed 2023-11-13 | $2.88K 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $73.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $128.28K 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | $55.24K 10-Q · filed 2023-05-12 | ||||
| 2022-12-31 | $168.81K 10-K · filed 2024-03-29 | $244.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |